Evaluation of Rhizoxin in Cancer Treatment
Author Information
Author(s): HL McLeod, LS Murray, J Wanders, A Setanoians, MA Graham, N Pavlidis, B Heinrich, WW ten Bokkel Huinink, DJTh Wagener, S Aamdal, J Verweij
Primary Institution: University of Glasgow
Hypothesis
Does rhizoxin demonstrate pharmacological efficacy in patients with various types of cancer?
Conclusion
Rhizoxin is rapidly eliminated from the body, and higher plasma concentrations are associated with better treatment responses in some patients.
Supporting Evidence
- Rhizoxin showed preclinical anti-tumor activity against various human tumor cell lines.
- Patients with higher rhizoxin plasma concentrations had better treatment responses.
- Pharmacokinetic studies indicated rapid elimination of rhizoxin from the body.
Takeaway
Rhizoxin is a medicine that helps fight cancer, but it leaves the body quickly, and some patients respond better to it than others.
Methodology
Patients received rhizoxin intravenously, and blood samples were taken to analyze drug levels and effects.
Potential Biases
Potential biases due to the non-mandatory nature of pharmacological study participation.
Limitations
The study had a small sample size and variability in patient responses, which may affect the reliability of the results.
Participant Demographics
Patients with melanoma, breast, head and neck, and non-small-cell lung cancers from various European countries.
Statistical Information
P-Value
0.03
Confidence Interval
95% CI -16 to -264
Statistical Significance
p=0.03
Want to read the original?
Access the complete publication on the publisher's website